• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $18 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-64 Mln

Xilio Therapeutics Inc. (XLO) Share Price

$0.72

As on 01-Mar-2024 16:00 EST

up-down-arrow $0.011.61%

  • Prev Close info

    $0.71

  • Day's Openinfo

    $0.76

  • Today's Highinfo

    $0.85

  • Today's Lowinfo

    $0.72

  • Today's Volumeinfo

    557,159

  • 52 Week rangeinfo

    $0.49 - 3.67

Please wait...

Xilio Therapeutics Inc. (XLO) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Xilio Therapeutics (XLO)
30.98 10.83 -19.96 -80.04 -- -- --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
Xilio Therapeutics (XLO)
-79.55 -83.19
S&P Small-Cap 600
13.89 -17.42
S&P BSE Sensex
18.74 4.44

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Xilio Therapeutics Inc. (XLO) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Xilio Therapeutics Inc. (XLO)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Xilio Therapeutics Inc. (XLO)

        President, CEO & Director

        Dr. Rene Russo BCPS, Pharm.D.

        Senior VP of Finance & Accounting

        Mr. Kevin M. Brennan

        Headquarters

        Waltham, MA

        FAQs for Xilio Therapeutics Inc. (XLO)

        The total asset value of Xilio Therapeutics Inc. (XLO) stood at $ 95 Mln as on 30-Sep-23

        The share price of Xilio Therapeutics Inc. (XLO) is $0.72 (NASDAQ) as of 01-Mar-2024 16:00 EST. Xilio Therapeutics Inc. (XLO) has given a return of -80.04% in the last 1 years.

        Xilio Therapeutics Inc. (XLO) has a market capitalisation of $ 18 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Xilio Therapeutics Inc. (XLO) is 0.35 times as on 29-Feb-2024, a -0.88% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Xilio Therapeutics Inc. (XLO) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Xilio Therapeutics Inc. (XLO) and enter the required number of quantities and click on buy to purchase the shares of Xilio Therapeutics Inc. (XLO).

        Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Address: 828 Winter Street, Waltham, MA, United States, 02451

        The CEO & director of Dr. Rene Russo BCPS, Pharm.D.. is Xilio Therapeutics Inc. (XLO), and CFO & Sr. VP is Mr. Kevin M. Brennan.

        The promoters of Xilio Therapeutics Inc. (XLO) have pledged 0% of the total equity as on Sep-23.

        Xilio Therapeutics Inc. (XLO) Ratios
        Return on equity(%)
        -115.28
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Xilio Therapeutics Inc. (XLO) was $-64 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $18.17 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-64.47 Mln
        • Cash date-information $59.77 Mln
        • Total Debt info $14.39 Mln
        • Insider's Holding 11.49%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $0.49 - 3.67
        • Shares outstanding share-outstanding 27,528,900
        • 5 Years Aggregate:

          CFO: $-283.82 Mln

          EBITDA: $-233.13 Mln

          Net Profit: $-315.34 Mln

        About The Company

        • IPO Date 22-Oct-2021
        • President, CEO & Director Dr. Rene Russo BCPS, Pharm.D.
        • Senior VP of Finance & Accounting Mr. Kevin M. Brennan
        • Listing key-listing NASDAQ: XLO
        • Country United States
        • Headquarters headquarters Waltham, MA
        • Website website https://xiliotx.com
        • Business

          Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that...  is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts. Address: 828 Winter Street, Waltham, MA, United States, 02451  Read more

        share-fund-plan-icon